TUCHMAN ALAN J 4/A
4/A · Synaptogenix, Inc. · Filed Dec 1, 2022
Insider Transaction Report
Form 4/AAmended
TUCHMAN ALAN J
DirectorChief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-11-15+68,850→ 68,850 totalExercise: $6.07Exp: 2032-11-15→ Common Stock, par value $0.0001 per share (68,850 underlying)
Footnotes (2)
- [F1]This filing amends the Form 4, filed on November 17, 2022 by Mr. Tuchman to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.
- [F2]These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.